Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494632 · ClinicalTrials.gov registry record · NA
Interaural Frequency and Loudness Mismatch in SSD CI Users
A NA study of Outcomes, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT05494632: Completed NA study of Outcomes, sponsored by Washington University School of Medicine.
NCT05494632 is a NA study of Outcomes that has completed, run by Washington University School of Medicine. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05494632, a NA study of Outcomes, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Interaural loudness and pitch mismatch in single-sided deaf cochlear implant (SSD-CI) recipients reduces binaural processing cues and contributes to performance outcomes, specifically speech understanding in noise and localization. The study aims to improve binaural cues through speech processor program modifications that reduce interaural mismatches.
Primary Outcome
Participants speech understanding was evaluated in the R-Space test environment with two speech processor programs, an everyday or default program and a modified program. The modified program was created to reduce interaural frequency or loudness mismatch between participants' CI ear and normal hearing ear. The R-Space simulates listening in a noisy restaurant, a real-world listening situation. The score is a signal-to-noise ratio that reflects 50% speech understanding in noise. Participants are
Conditions Studied
Interventions
- DEVICE Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients.
- DEVICE Treatment-modifications to CI speech processor program to reduced interaural frequency mismatch in newly implanted SSD-CI recipients.
- DEVICE Treatment-modifications to CI speech processor program to reduced interaural loudness mismatch in experienced SSD-CI recipients.
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2025-08-01 |
| Phase | NA |
What the finished NCT05494632 record still lists
NCT05494632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Outcomes appearing as the primary indexed condition, and to 3 interventions - of which Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients. is the first listed.
NCT05494632 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05494632 about?
NCT05494632 is a clinical study titled "Interaural Frequency and Loudness Mismatch in SSD CI Users". Interaural loudness and pitch mismatch in single-sided deaf cochlear implant (SSD-CI) recipients reduces binaural processing cues and contributes to performance outcomes, specifically speech understanding in noise and localization. The study aims to improve binaural cues through speech processor pro...
What is the current status of trial NCT05494632?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2022-08-12. Estimated completion is 2025-08-01.
What conditions does trial NCT05494632 study?
This clinical trial studies the following conditions: Outcomes.
What interventions are being tested in trial NCT05494632?
The interventions under investigation include: Treatment-modifications to CI speech processor program. Specifically reducing interaural frequency mismatch in experienced SSD-CI recipients. (DEVICE), Treatment-modifications to CI speech processor program to reduced interaural frequency mismatch in newly implanted SSD-CI recipients. (DEVICE), Treatment-modifications to CI speech processor program to reduced interaural loudness mismatch in experienced SSD-CI recipients. (DEVICE).
Who is sponsoring clinical trial NCT05494632?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05494632 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05494632's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI